Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Conditions
Interventions
Apremilast 30 mg
Apremilast 20 mg
+1 more
Locations
50
United States
ArthroCare, Arthritis Care Research
Gilbert, Arizona, United States
Arizona Research Center
Phoenix, Arizona, United States
TriWest Research Associates
La Mesa, California, United States
Desert Medical Advances
Palm Desert, California, United States
Stanford University Medical Center
Palo Alto, California, United States
Med Investigations/Sierra
Roseville, California, United States
Start Date
December 9, 2010
Primary Completion Date
February 21, 2012
Completion Date
September 10, 2012
Last Updated
May 8, 2020
NCT07536529
NCT06329401
NCT07048197
NCT07484243
NCT06647069
NCT06841562
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions